Drug name - Mayzent

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7939519 NOVARTIS Immunosuppresant compounds and compositions
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492441 NOVARTIS Dosage regimen of an S1P receptor agonist
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 26, 2024
M Mar 1, 2025

Drugs and Companies using SIPONIMOD FUMARIC ACID ingredient

Market Authorisation Date: 26 March, 2019

Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.25MG BASE TABLET;ORAL Prescription
EQ 1MG BASE TABLET;ORAL Prescription
EQ 2MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in